Clinical trials: HFpEF, active
Pulmonary Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)
Researchers are looking for other ways to treat people with combined postcapillary and precapillary pulmonary hypertension (CpcPH).
- Trial name
- CHORUS (NCT07839585)
- Testing
- Sotatercept
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Preserved Ejection Fraction
Precision Rehabilitation for Veterans With (HFpEF)
This study is being completed because there is conflicting information regarding the value of monitored exercise in patients with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT07493915
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia VA Health Care System
Heart Failure With Preserved Ejection Fraction (HFPEF)
HFpEF Phenotyping With Echo, Clinical, and Biomarkers
The EPIC-HFpEF registry is a nationwide Italian study that follows people with a specific type of heart failure called HFpEF. About 500 patients will be enrolled from several specialized hospitals and monitored for up to two…
- Trial name
- The EPIC-HFpEF (NCT07642921)
- Volunteers
- 500 people
- Sponsor
- University Of Perugia
Heart Failure, Diastolic
Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are…
- Trial name
- NCT04603404
- Where
- China
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atrial Fibrillation (AF)
Electroporation Treatment for Early AF Management in Heart Failure With Preserved Ejection Fraction (HFpEF) Pilot Study
The proposed pilot study is a prospective, randomized, single-center feasibility study, enrolling 200 patients with symptomatic paroxysmal AF.
- Trial name
- E-TEAM (NCT07385417)
- Testing
- AF Ablation
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction
Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare…
- Conditions
- HF - Heart Failure, HFpEF - Heart Failure With Preserved Ejection Fraction, Readmission Rates, Exercise Training
- Trial name
- EMPOWER-HFpEF (NCT07727096)
- Testing
- Exercise-Based Cardiac Rehabilitation, Guideline-Directed Medical Therapy
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Heart Failure With Preserved Ejection Fraction
Clinical Study of Active Intervention in High-risk HFpEF Patients
Based on inclusion and exclusion criteria, this experiment plans to include 924 Heart Failure with Preserved Ejection Fraction(HFpEF) patients with increased risk of all-cause death.
- Trial name
- NCT06532019
- Testing
- Targeted intervention based on risk factors
- Volunteers
- 924 people
- Sponsor
- Xiangtan Central Hospital
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Fontan Circulation, Single Ventricle Heart Disease
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT06762964
- Testing
- Dapagliflozin tablet
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
HFpEF - Heart Failure With Preserved Ejection Fraction
Role of Colchicine as Anti-Inflammatory Therapy in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a condition associated with high morbidity and mortality. Chronic low-grade inflammation plays a key role in its progression, yet few treatments specifically target this…
- Trial name
- CO-HFpEF (NCT06837623)
- Testing
- Colchicine Tablets
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Cairo University
HFpEF, LVDD
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with [angiotensin receptor/neprilysin inhibitor [ARNI]…
- Conditions
- HFpEF, LVDD, Myocardial Fibrosis
- Trial name
- NCT06655480
- Testing
- [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker]
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Tailored Exercise Training Study Among Adults With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF.
- Trial name
- TEXPEF (NCT07223242)
- Testing
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Preserved Ejection Fraction (HFpEF
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
This study will investigate whether intravenous (IV) iron improves symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency.
- Trial name
- ISLE HFpEF (NCT07643818)
- Testing
- Ferric Derisomaltose
- Where
- Jersey
- Volunteers
- 150 people
- Sponsor
- Government of Jersey
Heart Failure and Preserved Ejection Fraction, Obesity (Disorder)
OBESE-HFpEF: Towards Preventing Obesity Related HFpEF
Obesity, severe overweight, is a growing problem worldwide and increases the risk of heart failure, especially a type called heart failure with preserved ejection fraction (HFpEF). In HFpEF, the heart becomes stiffer.
- Conditions
- Heart Failure and Preserved Ejection Fraction, Obesity (Disorder), Heart Failure
- Trial name
- OBESE-HFpEF (NCT07539766)
- Where
- Netherlands
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
Heart Failure, Heart Failure With Preserved Ejection Fraction
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization…
- Trial name
- NCT06517186
- Where
- 6 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Heart Failure With Preserved Ejection Fraction (HFPEF)
Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction
Subjects undergo a gadolinium-based CMR followed by an iron infusion and then a repeat CMR in 72 hours
- Trial name
- NCT07634640
- Testing
- Ferumoxytol infusion
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Florida
Heart Failure With Preserved Ejection Fraction (HFPEF)
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood…
- Trial name
- EAT HFpEF (NCT06768437)
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- University of Leicester
HFpEF - Heart Failure With Preserved Ejection Fraction
HEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection Fraction
The goal of this study is to learn more about patients with heart failure with preserved ejection fraction (HFpEF) and exercise.
- Trial name
- NCT05784753
- Testing
- HEART Camp, HEART Camp Connect
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation)
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
- Trial name
- FINE-VALUE (NCT07575672)
- Testing
- Finerenone
- Where
- 61 sites in China
- Volunteers
- 2,832 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Heart Failure With Preserved Ejection Fraction
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism [Empagliflozin (Empa)], with and without additional supplements that increase perfusion and fatty acid oxidation…
- Trial name
- SAK (NCT05138575)
- Testing
- Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Pennsylvania